Editor's key points † This study analysed the influence of haemorrhage on the pseudo-steady-state remifentanil and propofol concentrations during co-administration in a porcine model. † Plasma remifentanil and propofol concentrations during continuous infusion both increase with progression of haemorrhage.
cological alterations might induce prolonged anaesthetic effects and accelerate further haemodynamic depression during shock. Therefore, both an appropriate reduction of the dose of i.v. anaesthetics and avoidance of the progression of haemorrhagic shock are required.
Previous studies using an isobaric or isovolaemic haemorrhage model have shown pharmacological alterations in advanced haemorrhagic shock; however, hypovolaemia varies in clinical practice and the relationship between the hypovolaemic level (or haemorrhagic shock stage) and the magnitude of the increase in concentration due to the pharmacokinetic alterations are unclear. In fact, we have shown in a porcine stepwise haemorrhage model that the plasma propofol concentration during continuous infusion increased by ,20% during compensated shock (i.e. the influence of pharmacokinetic alteration is minimal during compensated shock), but increased by 3.75 times during uncompensated shock, compared with the prehaemorrhage concentration. We concluded that the influence of haemorrhage on the plasma propofol concentration was not linear and differed depending on the stage of haemorrhagic shock. tissue and plasma esterases, thus not requiring delivery to the liver for metabolism, and has a small volume of distribution compared with propofol. 2 4 8 These differences in pharmacokinetic properties might lead to different changes in plasma concentrations in continuous infusion of remifentanil and propofol during haemorrhage. Previous pharmacokinetic studies have not examined increases in plasma concentrations in the use of both drugs in combination, and have not examined the magnitude of the increase in the remifentanil concentration as a function of the haemorrhagic stage. Therefore, the present study was conducted to investigate changes in pseudo-steady-state remifentanil and propofol concentrations during co-administration in a porcine stepwise haemorrhage model and to examine the effect of haemorrhagic stage on changes in the concentrations of both drugs. via mechanical ventilation. Exhalation gases were analysed using a Capnomac Ultima (ULT-V-31-04, Datex-Ohmeda, Helsinki, Finland). A ventilator was set to keep end-tidal carbon dioxide between 4.7 and 6 kPa during the animal preparation period, and this setting was maintained throughout the study. Lead II of an electrocardiogram was monitored with three cutaneous electrodes. A pulmonary artery catheter (5 F, 4 lumen, Nihon Kohden, Tokyo, Japan) and a central venous catheter (16 G) were inserted via the right jugular vein, and a catheter (16 G) was placed in the right femoral artery. All catheters were placed under local anaesthetic. The blood temperature of the swine was maintained at 37.5 -38.58C with heating lamps throughout the study. Haemodynamic responses to haemorrhage are biphasic. In the compensated shock state, there is a progressive increase in the central sympathetic vasoconstrictor drive and consequently arterial pressure is relatively maintained. However, after exceeding compensation, the uncompensated shock state occurs abruptly. Central systemic vasoconstrictor drive decreases, heart rate (HR) declines, and arterial pressure collapses. 9 In the present study, a decrease in HR did not necessarily occur before circulatory collapse. Therefore, we defined the period before peak systemic vascular resistance (SVR) as the compensated shock state and that after exceeding peak SVR as the uncompensated shock state. 7 
Methods

Animal preparation
Experimental protocol
Blood sampling and concentration assay
Arterial blood samples were obtained at 10, 20, 30, 40, 50, and 60 min after the start of propofol and remifentanil infusion to confirm that pseudo-steady-state concentrations were present before haemorrhage. Blood samples were also obtained every 30 min during stepwise bleeding until circulatory collapse. Blood samples of 2 ml were collected for measuring each drug concentration, with 40 ml of 50% (w/w) citric acid solution [20 ml of 50% (w/w) citric acid solution per millilitre of blood] included in the syringe used for collecting the blood sample for remifentanil determination to inhibit hydrolysis. Samples were centrifuged immediately at 48C for 10 min at 2000 rpm. The obtained plasma was stored at 2708C until analysis. Propofol concentrations were assayed by high-performance liquid chromatography based on the method of Plummer. 10 The lower limit of detection was 15 ng ml 21 and the inter-assay coefficient of variation was 7.3%. Remifentanil concentrations were assayed by liquid chromatography mass spectrometry using the method of Bossù and colleagues. 11 The lower limit of detection was 0.1 ng ml 21 and the inter-assay coefficients of variation were 7.6% at 1 ng ml 21 and 3.1% at 100 ng ml 21 .
Statistical analysis
Data are expressed as mean values with the SD in parentheses. Statistical analysis was performed using StatView 5.0
for Windows (Abacus Concepts, Berkeley, CA, USA). Haemodynamic and metabolic variables and the plasma concentration for each state were analysed by a repeated-measures one-way analysis of variance (ANOVA). If the ANOVA was found to be significant, a Scheffe F-test was performed for multiple comparisons. Linear regression equations for the relationship of cumulative blood loss (% estimated initial blood volume) and % increase from the prehaemorrhage plasma concentration were calculated by simple linear regression analysis using the least squares method for data in compensated or uncompensated shock stages. The pseudo-steady-state propofol concentration is expressed as dose rate/clearance, and clearance is given by F (fixed fraction)×CO; therefore, the pseudo-steady-state concentration linearly correlates with the reciprocal of CO. Several previous reports have shown an inverse relationship between concentration and CO varied by exogenous catecholamines 12 13 and alteration of the carbon dioxide tension. 14 Hence, the linear regression equations between the plasma remifentanil or propofol concentrations and the reciprocal of CO were calculated as in previous studies.
P-values of ,0.05 were considered to be statistically significant.
Results
One animal died after 45% bleeding, four died after 50% bleeding, three died after 55% bleeding, and one died after 60% bleeding. Before reaching circulatory collapse, a mean volume of 913 (82) ml of blood [49.6 (4.8)% of the estimated initial blood volume] was drained. The body temperature of all animals remained at 37.5 -38.58C throughout the study. The averaged haemodynamic and metabolic variables in each state are shown in Table 1 . Haemorrhage increased HR and lactate, and decreased MAP, CVP, CO, base excess, and haematocrit. Although the total fluid volume was only 127 (13) ml for measurements of CO throughout the experiment, the decrease in haematocrit might have been caused by dilution of the circulating blood due to absorption of fluid from interstitial spaces. SVR increased with increasing cumulative blood loss, reached a peak, and then decreased before circulatory collapse was reached in all animals. Individual changes in the plasma remifentanil and propofol concentrations are shown in Figure 1 . ively. Thus, both anaesthetics attained pseudo-steady-state concentrations after infusion for 60 min. The plasma concentrations of both anaesthetics increased with increasing cumulative blood loss, and marked increases occurred in the uncompensated shock stage in most animals. The relationships between the % increase from baseline concentration (concentration at 60 min) and cumulative blood loss (% estimated initial blood volume) for remifentanil and propofol are shown in Figure 2 . This figure shows the relationships between cumulative blood loss until each peak SVR in individual animals and the % increase from baseline concentration (compensated shock) and between cumulative blood loss after peak SVR and the % increase from baseline concentration (uncompensated shock). In different animals, 35% and 40% cumulative blood loss included both compensated and uncompensated shock states, indicating that the tolerance to high-volume blood loss varied among animals. The uncompensated shock state occurred in all animals after 45% bleeding. In the compensated shock stage, the % increase from baseline concentration fitted the following equations: % increase in remifentanil¼2.1× cumulative blood loss (% of estimated blood volume) (R 2 ¼0.84, P,0.0001); and % increase in propofol¼0.7×
cumulative blood loss (% of estimated blood volume) (R 2 ¼0.50, P,0.0001). In the uncompensated shock stage, % increase in remifentanil¼27.4×cumulative blood loss2897 (R 2 ¼0.38, P¼0.003); and % increase in propofol¼9.5×cumulative blood loss2309 (R 2 ¼0.23,
P¼0.0279).
When uncompensated shock occurred at 35% or 40% bleeding, the % increase from the baseline concentration was simulated by the equation for compensated shock until 30% or 35% bleeding and by the equation for uncompensated shock for more than 35% or 40% bleeding. Although the correlations were weaker for propofol compared with remifentanil, the slopes of these lines indicate that the increase in the remifentanil concentration was three times higher than that for propofol in both shock stages and the slope in uncompensated shock for each drug was 13 times larger than that in compensated shock. Haemodynamic and metabolic variables before haemorrhage, during compensated shock (at peak SVR), and during uncompensated shock before reaching circulatory collapse are shown in Table 2 . The plasma propofol concentration did not increase significantly, but the plasma remifentanil concentration increased by 93% during compensated shock. The drug concentrations increased to 2.6 and 5.4 times the respective prehaemorrhagic concentrations during uncompensated shock.
The relationships between the plasma concentrations and the reciprocal of CO are shown in Figure 3 . High linear correlations were observed, with remifentanil¼52.1/CO26.8 (R 2 ¼0.92, P,0.0001); and propofol¼4.3/CO+1.1 (R 2 ¼0.72, P,0.0001) (regression lines for these equations are not shown in Fig. 3) . Relationships between the reciprocal of CO and the concentration were examined for data on each side of peak SVR (compensated and uncompensated shock stage) in each animal. The slopes determined from data for compensated shock were 39.7 and 2.2 for remifentanil and propofol, respectively, and those for uncompensated shock were 54.4 and 4.8, respectively. Remifentanil and propofol concentrations in each shock stage were significantly correlated with the reciprocal of CO [P,0.0001, except for propofol in compensated shock (P¼0.005)].
Discussion
The current study showed that the plasma remifentanil and propofol concentrations during continuous infusion both increase with progression of haemorrhage. However, the increase in the remifentanil concentration was three times higher than that for propofol, indicating that the responses to this state differ between the two drugs. Furthermore, in the uncompensated state, both drug concentrations markedly increased, indicating that the effect on the plasma concentrations differs depending on the stage of haemorrhage. This is the first investigation of changes in the remifentanil concentration with progressive haemorrhage in co-administration with propofol. From previous studies investigating the pharmacokinetics of each drug separately during advanced haemorrhagic shock, it was difficult to determine differences between the drugs and the influence of haemorrhagic stage. It should be kept in mind that the remifentanil concentration greatly increases compared with propofol during total i.v. anaesthesia in haemorrhage.
The plasma propofol concentration did not significantly increase during compensated shock, but increased to 2.6 times the prehaemorrhagic concentration during uncompensated shock. The propofol concentration was considerably influenced by the decrease in CO during uncompensated shock, but hardly affected by the decrease in CO during compensated shock (Fig. 3) . These findings are consistent with our previous study 7 showed that the pseudo-steady-state concentration of remifentanil in haemorrhagic shock during continuous infusion was 2.4 times that in a control. In our study, the total mean shed blood volume was 34.7 (3.3) ml kg 21 body weight before circulatory collapse, which is somewhat less than that reported by Johnson and colleagues. However, the remifentanil concentration when MAP reached 40 mm Hg in each animal (uncompensated shock state in all animals) was 2.4 times higher than the prehaemorrhagic value, which is consistent with the results of Johnson and colleagues.
Since remifentanil concentrations at 30 min after the start of infusion were 95% of that at 60 min, the period of 30 min after each stepwise bleeding was sufficient for remifentanil to attain a pseudo-steady-state concentration. Therefore, the increase in concentration suggests decreases in central compartment volume and clearance. Although the effect of the same volume of blood loss was greater than for propofol and a significant increase was observed from compensated shock, the change in remifentanil concentration depending on the shock stage was similar to that of propofol. This indicates that decreases in central compartment volume and clearance markedly influence the uncompensated stage.
A remarkable characteristic of the % increases in remifentanil concentrations was that these were more than twice the cumulative blood loss (% estimated initial blood volume). In addition, the strong linear correlation between the remifentanil concentration and the reciprocal of CO was not related to the haemorrhage level, in contrast to propofol (Fig. 3) . Remifentanil is rapidly metabolized by tissue and plasma esterases and clearance does not depend on liver blood flow. These findings suggest that hydrolysis in tissue, rather than in circulatory blood, is the main contributor to metabolism of remifentanil and that perfusion of these tissues linearly depends on CO. Several previous studies have also suggested that tissue metabolism is the major site for remifentanil hydrolysis, and that the blood component contributes less to remifentanil metabolism. 8 15 Duthie and colleagues 16 showed that pulmonary extraction of remifentanil did not occur in adult patients undergoing elective cardiac surgery, but that clearance was related directly to CO. Remifentanil has the attractive feature that the pharmacokinetics are unlikely to be affected significantly by hepatic 17 or renal impairment; 18 however, pathological conditions with accompanying tissue hypoperfusion, similarly to the effects of haemorrhage, might increase the remifentanil concentration.
Several limitations of the study should be addressed. We used the plasma concentrations at 60 min after the start of continuous infusion as a reference for the results in the stepwise haemorrhage model, whereas interpretation of the data may be more reliable if a control group without haemorrhage had been included. We also note that our sampling time for the plasma concentrations (every 30 min after each haemorrhage) was not sufficient to attain an accurate steady-state concentration of propofol compared with remifentanil; hence, the differences in the increase in both concentrations might differ if the sampling time was changed. Finally, controlled unresuscitated haemorrhage during anaesthesia is not typical of clinical practice. Sufficient fluid resuscitation to maintain peripheral perfusion might not reduce hydrolysis by tissue esterases and the findings in the present study might not be observed. Therefore, further studies are required to investigate the influence of fluid resuscitation after severe haemorrhage on the plasma remifentanil concentration.
In summary, the remifentanil concentration during continuous infusion undergoes an increase that is three times higher than that for co-administered propofol with progression of haemorrhage. This result indicates that the remifentanil dose should be reduced substantially compared with propofol during total i.v. anaesthesia for patients with significant blood loss before or during surgery.
